News
Adding perioperative pembrolizumab to standard care can improve EFS in locally advanced head and neck cancer, data suggest.
Pembrolizumab (Keytruda) given before and after surgery to supplement adjuvant therapy improved responses and survival in ...
5d
MedPage Today on MSNNew Standard of Care in Locally Advanced Head and Neck CancerAdding pembrolizumab (Keytruda), before and after surgery, to standard adjuvant therapy for locally advanced head and neck ...
Can ctDNA-guided therapy stop cancer’s return, sparing patients unnecessary treatment? A new study suggests it might.
Pembrolizumab alone or in combination with chemotherapy can provide long-term benefits over chemotherapy alone in recurrent or metastatic HNSCC, data suggest.
Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...
Ravindra Uppaluri, MD, PhD, discussed the KEYNOTE-689 trial, which investigated pembrolizumab in locally advanced head and ...
The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...
4d
MedPage Today on MSNRA Doesn't Diminish Checkpoint Inhibitors' Survival BenefitIt had been hoped that RA patients might actually benefit more from these drugs, known as immune checkpoint inhibitors (ICIs), but that was not the case. Still, according to researchers led by Deanna ...
Our data clearly show that it is feasible and safe to implement stepwise acceleration of nivolumab and pembrolizumab administration to a 10-minute infusion time,” the researchers wrote.
A novel approach to tumor-infiltrating lymphocyte therapy yielded higher response rates among patients with metastatic ...
The findings suggest that enfortumab vedotin, especially combined with pembrolizumab, offers promising beneficial outcomes in metastatic urothelial carcinoma treatment,” researchers wrote.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results